Official company source
Retatrutide delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial.
Eli Lilly and Company. Retatrutide delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. News release, 2025-12-11.
Eli Lilly and CompanyPublished Dec 11, 2025Accessed Jul 12, 2026
Registry record
Source metadata
- Publisher
- Eli Lilly and Company
- Source type
- Official company source
- Registry ID
research-reta-07- Source code
- RETA-07
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.